Indacaterol
Clinical data | |
---|---|
Trade names | Onbrez, Arcapta |
AHFS/Drugs.com | International Drug Names |
License data |
|
Pregnancy category |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Indacaterol is an ultra-
dry powder inhaler
.
Medical uses
A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[7]
History
It was approved by the
United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.[9][10] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.[11]
References
- ^ "Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011". DailyMed. 1 April 2020. Retrieved 14 June 2021.
- ^ "Onbrez Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
- ^ "Oslif Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
- ^ "Hirobriz Breezhaler EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 January 2021.
- S2CID 11930383.
- PMID 17251236.
- PMID 25575340.
- ^ European Public Assessment Report for Onbrez Breezhaler Archived 2010-01-16 at the Wayback Machine
- ^ "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Archived from the original on 2011-07-03. Retrieved 2011-07-02.
- ^ "Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383". U.S. Food and Drug Administration. 13 August 2013. Retrieved 14 June 2021.
- ^ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.